A 24-Week, Multicenter, Randomized, Open-Label, 2-Arm Parallel-group Study Evaluating the Efficacy and Safety of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus

Trial Profile

A 24-Week, Multicenter, Randomized, Open-Label, 2-Arm Parallel-group Study Evaluating the Efficacy and Safety of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms TAKE-CONTROL
  • Sponsors Sanofi
  • Most Recent Events

    • 14 Sep 2017 According to a Sanofi media release, full results from the study will be presented in 2018.
    • 14 Sep 2017 Results published in a Sanofi media release.
    • 27 Jun 2017 This trial has been completed in Denmark.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top